An observational study in Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, sponsored by PROCEPT BioRobotics. Status unknown at 1 site in United Kingdom. Open to male participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-12-08.
Sponsored by PROCEPT BioRobotics · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Prostatic Hyperplasia with a site in United Kingdom — 2 open to participants now, 3 under way, none of them phase 3. Prostatic Hyperplasia · United Kingdom.
Among the 26 studies in Prostatic Hyperplasia with a site in United Kingdom, this one is one of 2 that started in 2021, is one of 6 observational ones, and was the 24th registered.
831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.
Browse Prostatic Hyperplasia studies →2 of the 26 studies in Prostatic Hyperplasia with a site in United Kingdom are open now. Recruiting first, the newest first:
Société Internationale d'Urologie · Sites in United Kingdom, United States, Canada and 18 more countries
Ages 18+ · Men only
Olympus Corporation of the Americas · Sites in United Kingdom, United States
Ages 50+ · Men only
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 45 Years to 85 Years · male.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 46 is below the median of 250 across 178 observational studies indexed under Prostatic Hyperplasia.
Median enrollment 400 across the 20 interventional studies, 409 across the 6 observational. Of the 21 that completed or were terminated, 12 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 26 have an industry lead sponsor. The 10 most frequent:
PROCEPT BioRobotics is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
PROCEPT BioRobotics has 9 studies filed under Prostatic Hyperplasia — fewer than ten, so there is no comparison to draw.
1 of the studies in Prostatic Hyperplasia with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04757116Olympus Corporation of the AmericasPost-Market Study to Assess iTind Safety in Comparison to UroLift | 2027-07-15 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Prostatic Hyperplasia with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A post-market, non-interventional, two-arm, long-term follow-up study of patients previously enrolled in the WATER Study (NCT02505919) - which was a prospective multi-centre randomized blinded study comparing Aquablation of the prostate with the AQUABEAM Robotic System with standard transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms (LUTS).
The study is a post-market, non-interventional, two-arm, long-term follow-up study of patients previously enrolled in the WATER Study (NCT02505919) - which was a prospective multi-centre randomized blinded study comparing Aquablation of the prostate with the AQUABEAM Robotic System with standard transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms (LUTS). In POST WATER, up to 46 WATER Study subjects in the United Kingdom who were active on the study at 36 months will be invited to participate, across 3 clinical study sites in England and Wales. The study will consist of one follow-up time-point at 60 months (5 years) from the time of initial WATER Study treatment date.
The target patient population is subjects who were enrolled in the WATER Study (with symptomatic BPH) who were randomized to treatment with either the Aquablation procedure or TURP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dementia or psychiatric condition that prevents the participant from completing required follow up 2. Participating in another study that could affect responses to the study assessments
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
WATER Study subjects previously-treated with Aquablation of the prostate with the AQUABEAM Robotic System for lower urinary tract symptoms associated with BPH.
WATER Study subjects previously-treated with standard transurethral resection of the prostate (TURP) for lower urinary tract symptoms associated with BPH.
Long-term effectiveness as measured by IPSS at 60 months
International Prostate Symptom Score at 60 months as compared to baseline
Time frame: 60 months following original surgical intervention
Long-term safety as measured by adverse events at 60 months
The proportion of subjects with adverse events classified as Clavien-Dindo Grade 2 or higher or any grade 1 event resulting in persistent disability
Time frame: 60 months following original surgical intervention
Reoperation or Re-intervention at 60 months
Reoperation or Re-intervention at 60 months
Time frame: 60 months
IPSS-QoL at 60 months
International Prostate Symptom Score Quality of Life sub-score
Time frame: 60 months
Qmax at 60 months
Uroflowmetry measurement of voided urine (in milliliters) per unit of time (in seconds)
Time frame: 60 months
PVR at 60 months
Post-void residual urine test
Time frame: 60 months
Erectile function at 60 months
IIEF-15 score
Time frame: 60 months
MSHQ-EjD at 60 months
Assessment of ejaculatory function/dysfunction
Time frame: 60 months
Plan to share: No
Start is estimated for Jan 2021; primary completion for Jan 2022, 12 months later.
Of 76 observational studies under Prostatic Hyperplasia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
PROCEPT BioRobotics